EMEA-000781-PIP01-09
Key facts
| Invented name |
Nexavar
|
| Active substance |
Sorafenib (as tosilate)
|
| Therapeutic area |
Oncology
|
| Decision number |
P/68/2010
|
| PIP number |
EMEA-000781-PIP01-09
|
| Pharmaceutical form(s) |
Film-coated tablet
|
| Condition(s) / indication(s) |
Differentiated thyroid cancer
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Bayer Schering Pharma AG
E-mail: pediatrics.medical-affairs-europe@bayerhealthcare.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|